Biofilm Eraser

B IOF ILM

ER A S E R A NEW APPLICATION FOR PERIODONTAL AND PERI-IMPLANT INFLAMMATION

Periodontitis, peri-implant mucositis and peri-implantitis are bacterial inflammations with similar symptoms. The underlying cause of all three indications, which progress in a similar way, is bacterial plaque forming a biofilm, rich in pathogenic bacteria. The softening of the biofilm and effective elimination of the bacteria is the key prerequisite for successful treatment of these conditions.4

Perisolv® is a new debridement gel used in addition to mechanical debridemen to precon- dition the treatment site by softening and degrading biofilm on tooth root/dental implant surface.

PERISOLV®-EFFECTS • Elimination of the biofilm* • Impoved peri-implant situation such as mucostitis1, 8 • Reduction of pocket depth2, 3

MODE OF ACTION MECHANICAL DEBRIDEMENT ALONE OR WITH PERISOLV®

BEFORE AFTER MECHANICAL DEBRIDEMENT

BIOFILM

* Enhancing bacterial removal by mechanical debridement. TREATMENT OF PERI-IMPLANT MUCOSITIS CASE BY PROF VINCENZO IORIO-SICILIANO, UNIVERSITY OF CATANZARO, ITALY

Implant with probing depth (PD) ≤ 5mm and BOP+.

Application of Perisolv® before non-surgical treatment.

Biofilm removal using a sonic scaler with PEEK tip.

6 MONTHS AFTER TREATEMENT Probing depth (PD) after 6 months observation time. TREATMENT OF A FURCATION DEFECT CASE BY PROF VINCENZO IORIO-SICILIANO, UNIVERSITY OF CATANZARO, ITALY

1. A PD of 5 mm was noted.

2. A class-II furcation defect was recorded.

1. 2.

3. First application of Perisolv®.

4. Scaling was performed using an ultrasonic device. 3. 4.

5. Second application of Perisolv®.

6. Root planing was performed.

5. 6.

6 MONTHS AFTER TREATEMENT 7. A PD of 3 mm was reported.

8. A class-I furcation defect with BOP- was 7. 8. recorded. FIVE REASONS TO USE CROSS-LINKED HYALURONIC ACID AFTER PERISOLV®

Attracts blood Stabilizes coagulum and supports tissue regeneration Bacteriostatic effect provides protection Growth factors attracted by hyaluronic acid Coordinates inflammation and accelerates angiogenesis

D LL IAG A NO EC S R E

L E

N H

S T EA EA L REP

Perisolv® can be used with Hyadent BG as part of the CLEAN&SEAL® concept. This treatment approach was developed based on scientific data,5, 6 provides guidance and support for the treatment and control of peri-implant and peridontal diseases.

The likelihood of success is further increased by the supportive application of sealing agents for protection and regenerative support and by regular follow-up to monitor and control inflammation.7 AVAILABLE PRODUCTS

PERISOLV Size Article number 5 x 0.6 ml syringes 0131.401

Size Article number 2 x 1.2 ml ampullas BS091 B IOF ILM

ER A S LITERATURE E R 1. Iorio-Siciliano V, Blasi A, Stratul SI, Ramaglia L, Sculean A, Salvi GE, Rusu D. Anti-infective therapy of peri-implant mucositis with adjunctive delivery of a sodium hypochlorite gel: a 6-month randomized triple-blind controlled clinical trial. Clin Oral Investig. 2020 Jun;24(6):1971-1979. doi: 10.1007/s00784-019-03060-2. Epub 2019 Aug 21. PMID: 31432311. 2. Guarnelli ME et al. ‘Professional local administration of chloramine-based treatment in conjunction with ultrasonic mechanical instrumentation: clinical outcomes in patients with deep periodontal pockets persisting following active non-surgical therapy’. Minerva Stomatologia, April 2015; Vol. 64 suppl. 1 al No. 2: 158-159. 3. Data on file. 4. Iorio-Siciliano V, Ramaglia L, Isola G, Blasi A, Salvi GE, Sculean A. Changes in clinical parameters following adjunctive local sodium hypochlorite gel in minimally invasive nonsurgical therapy (MINST) of periodontal pockets: a 6-month randomized controlled clinical trial. Clin Oral Investig. 2021 Mar 9. doi: 10.1007/s00784-021-03841-8. Epub ahead of print. PMID: 33687555. 5. Jepsen S et al. Primary prevention of periimplantitis: managing periimplant mucositis. J Clin Periodontol 2015; 42(Suppl. 16):S152-S157. doi: 10.1111/jcpe.12369. 6. Costa FO et al. Peri-implant disease in subjects with and without preventive maintenance: a 5-year follow-up. J Clin Periodontol 2012; 39(2): 173-183. doi: 10.1111/j.1600-051X.2011.01819.x. 7. Pirnazar P et al. Bacteriostatic effects of hyaluronic acid. J Periodontol 1999; 70(4): 370-374. doi: 10.1902/jop.1999.70.4.370. 8. Mayer Y, Ginesin O, Horwitz J. A nonsurgical treatment of peri-implantitis using mechanic, antiseptic and anti-inflammato- ry treatment: 1 year follow-up. Clin Exp Dent Res. 2020 Aug;6(4):478-485. doi: 10.1002/cre2.286. Epub 2020 Mar 17. PMID: 32185910; PMCID: PMC7453777.

Perisolv® is a registered trademark and is manufactured by REGEDENT AG. Hyadent BG is a registered brand and manufactured by BioScience GmbH.

Art. 8114.902EN, 2021-06-08